Source:http://linkedlifedata.com/resource/pubmed/id/19240085
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2010-6-17
|
| pubmed:abstractText |
Schizophrenia patients have a potential increased risk of metabolic dysregulation during antipsychotic treatments. Our objective was to compare changes in prolactin and metabolic variables (glucose, lipids and weight) as a post-hoc analysis from a six-month, randomised, controlled study of olanzapine (OLZ, n = 171; 10-20 mg/day) or quetiapine (QUE, n = 175; 300-700 mg/day). No statistically significant treatment group differences for baseline to endpoint mean changes in body mass index (P = 0.209) or weight (P = 0.250) were observed. There was a greater incidence of clinically significant weight gain (defined as > or =7% increase from baseline) in OLZ (19.2%) compared to QUE (13.2%)-treated patients (P = 0.181). No statistically significant treatment group differences for lipids and glucose variables, either as mean change from baseline to endpoint or treatment-emergent (TE) categorical changes were found (P > or = 0.05). Incidence rates for TE diabetes were similar between treatment groups 2.5% (n = 4) in the OLZ-treatment group and 1.3% (n = 2) in the QUE-treatment group (P = 0.685). Hyperprolactinaemia was present at baseline in many patients (OLZ 32.9%; QUE 31.4%), but after 2 weeks of treatment prolactin values had reverted to normal for nearly all patients (OLZ 100%; QUE 99.4%). There were no significant treatment differences in any variable between cohorts.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Benzodiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Blood Glucose,
http://linkedlifedata.com/resource/pubmed/chemical/Dibenzothiazepines,
http://linkedlifedata.com/resource/pubmed/chemical/Prolactin,
http://linkedlifedata.com/resource/pubmed/chemical/olanzapine,
http://linkedlifedata.com/resource/pubmed/chemical/quetiapine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1461-7285
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1001-9
|
| pubmed:meshHeading |
pubmed-meshheading:19240085-Adult,
pubmed-meshheading:19240085-Aged,
pubmed-meshheading:19240085-Antipsychotic Agents,
pubmed-meshheading:19240085-Benzodiazepines,
pubmed-meshheading:19240085-Blood Glucose,
pubmed-meshheading:19240085-Body Mass Index,
pubmed-meshheading:19240085-Body Weight,
pubmed-meshheading:19240085-Dibenzothiazepines,
pubmed-meshheading:19240085-Double-Blind Method,
pubmed-meshheading:19240085-Female,
pubmed-meshheading:19240085-Humans,
pubmed-meshheading:19240085-Lipid Metabolism,
pubmed-meshheading:19240085-Male,
pubmed-meshheading:19240085-Middle Aged,
pubmed-meshheading:19240085-Prolactin,
pubmed-meshheading:19240085-Psychotic Disorders,
pubmed-meshheading:19240085-Schizophrenia,
pubmed-meshheading:19240085-Schizophrenic Psychology,
pubmed-meshheading:19240085-Weight Gain
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
|
| pubmed:affiliation |
Eli Lilly and Company, Basingstoke, UK. bushe_chris@lilly.com
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study
|